ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies |
| |
| Authors: | Stephen J. Nicholls Allan Gordon Jan Johannson Christie M. Ballantyne Philip J. Barter H. Bryan Brewer John J. P. Kastelein Norman C. Wong Marilyn R. N. Borgman Steven E. Nissen |
| |
| Affiliation: | (1) Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, USA;(2) Resverlogix Corporation, Calgary, Canada;(3) Baylor Medical Center, Houston, USA;(4) Heart Research Institute, Sydney, Australia;(5) Medstar Research Institute, Washington DC, USA;(6) Academic Medical Center, Amsterdam, the Netherlands;(7) Department of Cardiovascular Medicine, Mail Code JJ-65, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA |
| |
| Abstract: | Background Considerable interest has focused on the development of therapies that target the functionality of high-density lipoproteins (HDL). Upregulation of endogenous synthesis of the major protein on HDL particles, apolipoprotein A-I (apoA-I), represents a novel approach to generation of new HDL particles. The Study of Quantitative Serial Trends in Lipids with Apolipoprotein A-I Stimulation (SUSTAIN, NCT01423188) study aims to evaluate the lipid efficacy, safety and tolerability of an apoA-I inducer (RVX-208). The ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE, NCT01067820) study aims to evaluate the effect of RVX-208 on plaque burden. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
